| Pivotal role of mTOR signaling in hepatocellular carcinoma A Villanueva, DY Chiang, P Newell, J Peix, S Thung, C Alsinet, V Tovar, ... Gastroenterology 135 (6), 1972-1983. e11, 2008 | 826 | 2008 |
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, ... Cancer research 68 (16), 6779-6788, 2008 | 733 | 2008 |
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes D Sia, Y Hoshida, A Villanueva, S Roayaie, J Ferrer, B Tabak, J Peix, ... Gastroenterology 144 (4), 829-840, 2013 | 560 | 2013 |
| Predicting the mutations generated by repair of Cas9-induced double-strand breaks F Allen, L Crepaldi, C Alsinet, AJ Strong, V Kleshchevnikov, P De Angeli, ... Nature biotechnology 37 (1), 64-72, 2019 | 460 | 2019 |
| Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma A Villanueva, Y Hoshida, C Battiston, V Tovar, D Sia, C Alsinet, ... Gastroenterology 140 (5), 1501-1512. e2, 2011 | 450 | 2011 |
| Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice A Villanueva, C Alsinet, K Yanger, Y Hoshida, Y Zong, S Toffanin, ... Gastroenterology 143 (6), 1660-1669. e7, 2012 | 351 | 2012 |
| Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib A Lachenmayer, C Alsinet, R Savic, L Cabellos, S Toffanin, Y Hoshida, ... Clinical cancer research 18 (18), 4997-5007, 2012 | 327 | 2012 |
| UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma R Mudbhary, Y Hoshida, Y Chernyavskaya, V Jacob, A Villanueva, MI Fiel, ... Cancer Cell 25 (2), 196-209, 2014 | 308 | 2014 |
| IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage V Tovar, C Alsinet, A Villanueva, Y Hoshida, DY Chiang, M Solé, S Thung, ... Journal of hepatology 52 (4), 550-559, 2010 | 289 | 2010 |
| Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo P Newell, S Toffanin, A Villanueva, DY Chiang, B Minguez, L Cabellos, ... Journal of hepatology 51 (4), 725-733, 2009 | 273 | 2009 |
| MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a S Toffanin, Y Hoshida, A Lachenmayer, A Villanueva, L Cabellos, ... Gastroenterology 140 (5), 1618-1628. e16, 2011 | 264 | 2011 |
| Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib A Lachenmayer, S Toffanin, L Cabellos, C Alsinet, Y Hoshida, ... Journal of hepatology 56 (6), 1343-1350, 2012 | 221 | 2012 |
| Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma V Tovar, H Cornella, A Moeini, S Vidal, Y Hoshida, D Sia, J Peix, ... Gut 66 (3), 530-540, 2017 | 184 | 2017 |
| New strategies in hepatocellular carcinoma: genomic prognostic markers A Villanueva, Y Hoshida, S Toffanin, A Lachenmayer, C Alsinet, R Savic, ... Clinical Cancer Research 16 (19), 4688-4694, 2010 | 144 | 2010 |
| Unique genomic profile of fibrolamellar hepatocellular carcinoma H Cornella, C Alsinet, S Sayols, Z Zhang, K Hao, L Cabellos, Y Hoshida, ... Gastroenterology 148 (4), 806-818. e10, 2015 | 129 | 2015 |
| Molecular approaches to treatment of hepatocellular carcinoma A Lachenmayer, C Alsinet, CY Chang, JM Llovet Digestive and Liver Disease 42, S264-S272, 2010 | 128 | 2010 |
| IGF2 is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and is an Actionable Oncogene Product in Experimental Models I Martinez-Quetglas, R Pinyol, D Dauch, S Torrecilla, V Tovar, A Moeini, ... Gastroenterology 151 (6), 1192-1205, 2016 | 120 | 2016 |
| Genomic determinants of protein abundance variation in colorectal cancer cells TI Roumeliotis, SP Williams, E Gonçalves, C Alsinet, ... Cell reports 20 (9), 2201-2214, 2017 | 112 | 2017 |
| VEGF signaling in cancer treatment D Sia, C Alsinet, P Newell, A Villanueva Current pharmaceutical design 20 (17), 2834-2842, 2014 | 109 | 2014 |
| DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival L Cornell, JM Munck, C Alsinet, A Villanueva, L Ogle, CE Willoughby, ... Clinical Cancer Research 21 (4), 925-933, 2015 | 94 | 2015 |
